Sermorelin

Sermorelin (GHRH 1-29) is a synthetic analog of the first 29 amino acids of human growth-hormone-releasing hormone (GHRH). Rather than delivering exogenous GH directly, it signals the pituitary gland to produce and release your body's own growth hormone, preserving the natural hypothalamic-pituitary feedback loop that limits over-stimulation.

Sermorelin was historically marketed as Geref (sermorelin acetate), an FDA-approved agent for diagnosing and treating GH deficiency in children. The branded product was voluntarily discontinued by the manufacturer in the early 2000s for commercial reasons unrelated to safety [1]. Today sermorelin is dispensed exclusively as a compounded prescription medication by licensed pharmacies under prescriber supervision.

Off-label interest has grown among adult-wellness practitioners who use it to support GH-axis function during age-related GH decline (sometimes called somatopause). The evidence base is substantially stronger for the pediatric indication than for adult anti-aging use, and no large, long-term, placebo-controlled RCTs in healthy aging adults have been published.

Sermorelin binds to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary, activating cAMP signaling and stimulating pulsatile GH synthesis and secretion. Because pituitary output remains subject to normal somatostatin inhibition, the body's feedback control over GH remains intact — a key physiologic difference from direct exogenous GH injection [6]. Plasma half-life after subcutaneous administration is short (approximately 10–12 minutes), so GH stimulation is transient and pulse-like rather than sustained.

Downstream, released GH drives hepatic IGF-1 production, which mediates most of the anabolic, lipolytic, and tissue-repair effects attributed to GH. Because sermorelin requires a functional pituitary to work, patients with significant pituitary damage — including from prior radiation — may have blunted or absent responses [5].

The strongest clinical evidence for sermorelin is in pediatric GH deficiency. A multicenter trial by Thorner et al. (the Geref International Study Group) demonstrated that once-daily subcutaneous GHRH(1-29) therapy significantly accelerated growth velocity in GHD children during the first year of treatment [2]. Kirk et al. similarly reported sustained growth-velocity increases in children with idiopathic short stature given GHRH(1-29)NH2 [3]. A comprehensive review of the sermorelin literature concluded it was an effective alternative to exogenous rhGH for idiopathic pediatric GHD, with comparable tolerability [1].

Evidence in adults is more limited and mechanistically inferential. Khorram et al. conducted a controlled study of long-term [Nle27]GHRH-(1-29)-NH2 (a sermorelin-like analog) in older men and women, finding enhanced GH secretion and favorable trends in body composition compared to baseline — though the trial was small and used an analog that is not identical to standard sermorelin [4]. Ogilvy-Stuart et al. reported that GHRH treatment partially restored GH secretion in patients whose GH axis had been damaged by radiation therapy [7].

A study by Achermann et al. found that the GH response to low-dose GHRH(1-29) was markedly attenuated in patients with longstanding post-irradiation GH insufficiency, reinforcing that residual pituitary reserve is required for the peptide to be effective [5]. No published human RCT has evaluated sermorelin's effect on lean mass, fat mass, sleep quality, or libido as a primary endpoint in healthy aging adults; such claims are extrapolated from GH physiology.

Compounding prescribers commonly use doses of 200–500 mcg administered by subcutaneous injection once daily, typically before bedtime to coincide with the body's natural nocturnal GH pulse. Some protocols split the dose into two injections — one in the morning and one at night. Injectable delivery is considered more reliably bioavailable than oral troches, though both forms are offered [6].

IGF-1 levels are typically measured at baseline and every 3–6 months during therapy to confirm a biological response and guide dose adjustments. Because no FDA-approved dosing regimen exists for adult off-label use, clinical protocols vary among prescribers. A trial of at least 3–6 months is generally recommended before evaluating meaningful changes in body composition.

As a compounded peptide, sermorelin is not subject to the manufacturing oversight applied to FDA-approved drug products, and sterility, potency, and purity can vary across compounding pharmacies. Commonly reported side effects include transient injection-site redness or swelling, flushing, and headache [1]. Because sermorelin depends on intact pituitary function, it will not raise GH in patients with significant hypopituitary damage.

Sermorelin preserves hypothalamic somatostatin feedback, which theoretically limits the risk of pathological GH excess compared to exogenous rhGH — but this theoretical safety advantage has not been tested in head-to-head controlled trials. Sermorelin should not be used by individuals with active or history of malignancy, given that the GH/IGF-1 axis is growth-promoting. All use in otherwise healthy adults is off-label.